Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis

Background When an immune cell migrates from the bloodstream to a site of chronic inflammation, it experiences a profound decrease in microenvironmental oxygen levels leading to a state of cellular hypoxia. The hypoxia-inducible factor-1α (HIF-1α) promotes an adaptive transcriptional response to hyp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Manresa, Mario C. (VerfasserIn) , Radhakrishnan, Praveen (VerfasserIn) , Schneider, Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [April 2019]
In: Allergy
Year: 2018, Jahrgang: 74, Heft: 4, Pages: 753-766
ISSN:1398-9995
DOI:10.1111/all.13655
Online-Zugang:Verlag, Volltext: https://doi.org/10.1111/all.13655
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13655
Volltext
Verfasserangaben:Mario C. Manresa, Leila Smith, Laura Casals‐Diaz, Raphael R. Fagundes, Eric Brown, Praveen Radhakrishnan, Stephen J. Murphy, Bianca Crifo, Moritz J. Strowitzki, Doug N. Halligan, Ellen H. van den Bogaard, Hanna Niehues, Martin Schneider, Cormac T. Taylor, Martin Steinhoff

MARC

LEADER 00000caa a2200000 c 4500
001 1665913592
003 DE-627
005 20230427160300.0
007 cr uuu---uuuuu
008 190520r20192018xx |||||o 00| ||eng c
024 7 |a 10.1111/all.13655  |2 doi 
035 |a (DE-627)1665913592 
035 |a (DE-599)KXP1665913592 
035 |a (OCoLC)1341224995 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Manresa, Mario C.  |e VerfasserIn  |0 (DE-588)1209715562  |0 (DE-627)1697702643  |4 aut 
245 1 0 |a Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis  |c Mario C. Manresa, Leila Smith, Laura Casals‐Diaz, Raphael R. Fagundes, Eric Brown, Praveen Radhakrishnan, Stephen J. Murphy, Bianca Crifo, Moritz J. Strowitzki, Doug N. Halligan, Ellen H. van den Bogaard, Hanna Niehues, Martin Schneider, Cormac T. Taylor, Martin Steinhoff 
264 1 |c [April 2019] 
300 |b Illustrationen 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First published: 05 November 2018 
500 |a Gesehen am 20.05.2019 
520 |a Background When an immune cell migrates from the bloodstream to a site of chronic inflammation, it experiences a profound decrease in microenvironmental oxygen levels leading to a state of cellular hypoxia. The hypoxia-inducible factor-1α (HIF-1α) promotes an adaptive transcriptional response to hypoxia and as such is a major regulator of immune cell survival and function. HIF hydroxylases are the family of oxygen-sensing enzymes primarily responsible for conferring oxygen dependence upon the HIF pathway. Methods Using a mouse model of allergic contact dermatitis (ACD), we tested the effects of treatment with the pharmacologic hydroxylase inhibitor DMOG, which mimics hypoxia, on disease development. Results Re-exposure of sensitized mice to 2,4-dinitrofluorobenzene (DNFB) elicited inflammation, edema, chemokine synthesis (including CXCL1 and CCL5) and the recruitment of neutrophils and eosinophils. Intraperitoneal or topical application of the pharmacologic hydroxylase inhibitors dymethyloxalylglycine (DMOG) or JNJ1935 attenuated this inflammatory response. Reduced inflammation was associated with diminished recruitment of neutrophils and eosinophils but not lymphocytes. Finally, hydroxylase inhibition reduced cytokine-induced chemokine production in cultured primary keratinocytes through attenuation of the JNK pathway. Conclusion These data demonstrate that hydroxylase inhibition attenuates the recruitment of neutrophils to inflamed skin through reduction of chemokine production and increased neutrophilic apoptosis. Thus, pharmacologic inhibition of HIF hydroxylases may be an effective new therapeutic approach in allergic skin inflammation. 
534 |c 2018 
700 1 |a Radhakrishnan, Praveen  |d 1985-  |e VerfasserIn  |0 (DE-588)1082783137  |0 (DE-627)84779220X  |0 (DE-576)455565694  |4 aut 
700 1 |a Schneider, Martin  |d 1976-  |e VerfasserIn  |0 (DE-588)12390384X  |0 (DE-627)706468147  |0 (DE-576)42325037X  |4 aut 
773 0 8 |i Enthalten in  |t Allergy  |d Oxford : Wiley, 1978  |g 74(2019), 4, Seite 753-766  |h Online-Ressource  |w (DE-627)320425428  |w (DE-600)2003114-2  |w (DE-576)091140153  |x 1398-9995  |7 nnas  |a Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis 
773 1 8 |g volume:74  |g year:2019  |g number:4  |g pages:753-766  |g extent:14  |a Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis 
856 4 0 |u https://doi.org/10.1111/all.13655  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13655  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190520 
993 |a Article 
994 |a 2019 
998 |g 12390384X  |a Schneider, Martin  |m 12390384X:Schneider, Martin  |d 910000  |d 910200  |e 910000PS12390384X  |e 910200PS12390384X  |k 0/910000/  |k 1/910000/910200/  |p 13 
998 |g 1082783137  |a Radhakrishnan, Praveen  |m 1082783137:Radhakrishnan, Praveen  |d 910000  |d 910200  |e 910000PR1082783137  |e 910200PR1082783137  |k 0/910000/  |k 1/910000/910200/  |p 6 
999 |a KXP-PPN1665913592  |e 3478215315 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"display":"Manresa, Mario C.","role":"aut","roleDisplay":"VerfasserIn","given":"Mario C.","family":"Manresa"},{"family":"Radhakrishnan","role":"aut","roleDisplay":"VerfasserIn","given":"Praveen","display":"Radhakrishnan, Praveen"},{"display":"Schneider, Martin","given":"Martin","role":"aut","roleDisplay":"VerfasserIn","family":"Schneider"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1978","publisherPlace":"Oxford ; Oxford","publisher":"Wiley ; Blackwell Munksgaard","dateIssuedDisp":"1978-"}],"language":["eng"],"disp":"Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitisAllergy","title":[{"title_sort":"Allergy","title":"Allergy"}],"id":{"zdb":["2003114-2"],"eki":["320425428"],"issn":["1398-9995"],"doi":["10.1111/(ISSN)1398-9995"]},"pubHistory":["33.1978 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 14.08.14"],"recId":"320425428","part":{"issue":"4","volume":"74","pages":"753-766","extent":"14","year":"2019","text":"74(2019), 4, Seite 753-766"}}],"name":{"displayForm":["Mario C. Manresa, Leila Smith, Laura Casals‐Diaz, Raphael R. Fagundes, Eric Brown, Praveen Radhakrishnan, Stephen J. Murphy, Bianca Crifo, Moritz J. Strowitzki, Doug N. Halligan, Ellen H. van den Bogaard, Hanna Niehues, Martin Schneider, Cormac T. Taylor, Martin Steinhoff"]},"id":{"eki":["1665913592"],"doi":["10.1111/all.13655"]},"origin":[{"dateIssuedDisp":"[April 2019]","dateIssuedKey":"2019"}],"physDesc":[{"extent":"14 S.","noteIll":"Illustrationen"}],"title":[{"title_sort":"Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis","title":"Pharmacologic inhibition of hypoxia-inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1665913592","note":["First published: 05 November 2018","Gesehen am 20.05.2019"]} 
SRT |a MANRESAMARPHARMACOLO2019